ESMO Asia 2022 | Which patients with gastric cancer can benefit most from checkpoint inhibitors?
Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, discusses the current state of using predictive biomarkers for immunotherapy for patients with gastric cancer. Dr Shitara discusses which patients are most likely to benefit from the use of checkpoint inhibitors and explains the various points of view on this topic. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
A position of a board member or advisor: Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Merck Pharmaceutical, Taiho Pharmaceutical, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan, and Janssen
Honoraria for lectures: Takeda, Janssen and Bristol-Myers Squibb
Clinical research grants: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Medi Science, Eisai and Amgen
